There is evidence indicating that MIP-1β can promote the development of tumours by inducing protumorigenic macrophages, regulatory T-cell infiltration and other chemokines to suppress tumour immunity; conversely, MIP-1β can ramp up tumour immunity by recruiting macrophages with phagocytic ability and cytolytic lymphocytes [31]. This evidence concerns the gene CCL4 and neoplasm.